Advancing metastatic prostate cancer care: best practices and future directions in molecular testing
Authors:
- Elena CastroElena Castro
- Jie-Fu ChenJCJie-Fu Chen
- Ben LowentrittBLBen Lowentritt
- Partha DasPDPartha Das
- Ramin DowlatiRDRamin Dowlati
- David OlmosDODavid Olmos
Open Access
- 14 June 2026
- journal article
- Published by Elsevier in Prostate International
Abstract
No abstract availableFunding Information
- Johnson and Johnson
This publication has 61 references indexed in Scilit:
- Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical ValueAdvances in Therapy, 2024
- 1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)Annals of Oncology, 2023
- Rapid on‐site evaluation (ROSE) of image‐guided FNA specimens improves subsequent core biopsy adequacy in clinical trial patients: The impact of preanalytical factors and its correlation with survivalCancer Cytopathology, 2023
- Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialAnnals of Oncology, 2023
- Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendationsAnnals of Oncology, 2022
- Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing GuidelinesJAMA Network Open, 2022
- Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNAJAMA Oncology, 2021
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Bone biopsy protocol for advanced prostate cancer in the era of precision medicineCancer, 2017
- Evaluation of Hybridization Capture Versus Amplicon‐Based Methods for Whole‐Exome SequencingHuman Mutation, 2015